Affordable Access

Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial.

Authors
  • Scheithauer, W
  • Cortelezzi, A
  • Fritz, E
  • Kührer, I
  • Polli, E
  • Baldini, L
  • Ludwig, H
Type
Published Article
Journal
Journal of biological response modifiers
Publication Date
Apr 01, 1989
Volume
8
Issue
2
Pages
109–115
Identifiers
PMID: 2659740
Source
Medline
License
Unknown

Abstract

Thirty-three previously untreated patients with multiple myeloma were randomized to either a combination of recombinant interferon-alpha-2C (rIFN-alpha-2C) plus vincristine/melphalan/cyclophosphamide and prednisone (VMCP) or VMCP chemotherapy alone. The combined regimen effected 67% responses and 26% minor responses, while 35 and 47% of VMCP-treated patients had a pathologically documented remission, respectively. Despite the somewhat earlier achievement and duration (12.0 vs. 8.0 months) of objective response, and the marginal survival benefit observed in the rIFN-alpha-2C + VMCP treatment arm, a significant improvement in therapeutic gain by adding a biologic response modifier to conventional first-line polychemotherapeutic drug treatment in myeloma patients has not yet been achieved. The combined regimen was well tolerated without unusual or unexpected toxic effects.

Report this publication

Statistics

Seen <100 times